Komori
Earnings presentation materials4527ROHTO PHARMACEUTICAL CO.,LTD.Pharmaceuticals

Second-Quarter (Interim) Results Briefing for the Fiscal Year Ending March 2027

For the interim period of the fiscal year ending March 2027, revenue and operating profit increased, with revenue reaching a record high for an interim period. Ordinary profit and interim net income attributable to owners of the parent declined, while the full-year forecast was left unchanged on a consolidated basis, with regional forecasts revised.

Worth reading
73In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
179006
¥ million (interim-period revenue)
Wording
Conditional
How definitive the wording is.

Contents of this document

Earnings presentation materialsSecond quarter (interim period) of the fiscal year ending March 202711 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥179,006 million+9.0%
Operating profit¥20,953 million+8.5%
Ordinary income¥21,845 million-11.2%
Net income¥16,498 million -6.5%interim net income attributable to owners of the parent
Gross Profit Margin55.6
Operating profit margin11.7
Selling, general and administrative expenses¥78,608 million
Results for the three months of the current quarter
Net Sales
¥87,382 million+6.2%
Operating profit
¥7,290 million-4.3%
Ordinary income
¥7,353 million-13.3%
Net income
¥5,847 million -0.6%profit attributable to owners of the parent
Full-year earnings forecast
Net Sales
¥372,300 million
Operating profit
¥45,000 million
Ordinary income
¥47,400 million
Net income
¥35,200 million net income attributable to owners of the parent
EBITDA
¥63,700 million
Earnings per share
¥156.5
Progress against full-year forecast　通期の予想に対して、いまどこまで進んだかの割合です。
Net Sales48.1 %
Operating profit46.6 %
Ordinary income46.1 %
Net income46.9 %
EBITDA47.2 %
By segment
Japan revenue49.4
Asia sales47
US sales45.8
Europe sales47.3
Other sales49.5
Total overseas sales47
Japan operating profit51
Asia operating profit46.4
Europe operating profit42.2
Other operating profit30.7
Operating income adjustments57.6
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Change in operating income
Higher profits at EYS, China, Rohto standalone, Malaysia, DAX, etc.8,187
Higher profits at Rohto standalone and QTP191
Lower profits in Vietnam, China, DAX, etc.-1,208
Lower profits in China, Malaysia, EYS, etc.-1,132
Lower profits in China, Rohto standalone, etc.-264
Impact of personnel expenses, etc.-1,903
Other factors contributing to lower profits-2,233
Operating income impact
Foreign exchange impact889
Impact of higher sales8,100
Impact of personnel expenses-1,900
Cost impact190
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Foreign exchange (USD/JPY)158
Foreign exchange (CNY/JPY)23
New initiatives
  • Strategic Enterprise Partnership Agreement with the Hong Kong government’s OASES
  • Holding a Global Sustainability Meeting
  • Establishment of a voluntary review committee composed solely of independent outside directors
  • Acquisition of the Pain Away brand business and commencement of operations
  • Acquisition of Magic Cod d.o.o.
  • Launch of phyto-exosome technology as a mass-market self-brand next spring
Key KPIsA metric the company considers important as a management benchmark.
  • EBITDA¥30,071 million
    Year on year against the same period last year+9.8%
  • Hada Labo sales
    Year on year against the same period last year+5.6%
  • Rohto V5 sales
    Year on year against the same period last year+13.8%
  • Obagi sales
    Year on year against the same period last year+3.5%
  • Premium eye-drop sales
    Year on year against the same period last year+9.8%
  • Melano CC sales
    Year on year against the same period last year-5.8%
  • Sunscreen sales
    Year on year against the same period last year-18.1%
Segment results
Japan
Net Sales
¥86,070 million+3.0%
Operating profit
¥11,943 million+8.0%
Asia
Net Sales
¥67,160 million+17.1%
Operating profit
¥8,025 million+12.4%
United States
Net Sales
¥10,344 million+2.3%
Operating profit
¥-403 million-194.3%
Europe
Net Sales
¥13,351 million+15.7%
Operating profit
¥717 million+218.5%
Other
Net Sales
¥2,078 million+22.0%
Operating profit
¥153 million+29.3%
Medium-term management plan targets
Operating cash flow (before deducting R&D expenses)¥380 billion (six years from 2026 through 2031)
Capital Expenditure¥110 billion (six years from 2026 through 2031)
Research and Development Expenses¥100 billion (six years from 2026 through 2031)
DX/IT investment¥35 billion (six years from 2026 through 2031)
M&A and other activities¥70 billion (six years from 2026 through 2031)
Financial targets
Payout ratioAt least 30%
DOE3.5% or higher
2030 dividend payout ratioExpected to be 40%
Capital expenditures
¥10,485 million interim period
Annual Dividend
Annual¥50
Interim¥25
End of period¥25
Payout ratio
31.9
Acquisition of treasury shares
¥3 billion
PeriodEnded on 14 September 2026
Contents of this document
ItemDetails
Document typeEarnings presentation materials
Fiscal Period CoveredSecond quarter (interim period) of the fiscal year ending March 2027
Net Sales¥179,006 million (YoY +9.0%)
Operating profit¥20,953 million (YoY +8.5%)
Ordinary income¥21,845 million (YoY -11.2%)
Net income¥16,498 million (interim net income attributable to owners of the parent) (YoY -6.5%)
Gross Profit Margin55.6
Operating profit margin11.7
Selling, general and administrative expenses¥78,608 million
Results for the three months of the current quarterNet Sales ¥87,382 million (YoY +6.2%) / Operating profit ¥7,290 million (YoY -4.3%) / Ordinary income ¥7,353 million (YoY -13.3%) / Net income ¥5,847 million (profit attributable to owners of the parent) (YoY -0.6%)
Full-year earnings forecastNet Sales ¥372,300 million / Operating profit ¥45,000 million / Ordinary income ¥47,400 million / Net income ¥35,200 million (net income attributable to owners of the parent) / EBITDA ¥63,700 million / Earnings per share ¥156.5
Progress against full-year forecastNet Sales 48.1 % / Operating profit 46.6 % / Ordinary income 46.1 % / Net income 46.9 % / EBITDA 47.2 % / By segment Japan revenue 49.4 / Asia sales 47 / US sales 45.8 / Europe sales 47.3 / Other sales 49.5 / Total overseas sales 47 / Japan operating profit 51 / Asia operating profit 46.4 / US operating profit Not disclosed / Europe operating profit 42.2 / Other operating profit 30.7 / Operating income adjustments 57.6
Segment resultsJapan Net Sales ¥86,070 million (YoY +3.0%) / Operating profit ¥11,943 million (YoY +8.0%) / Asia Net Sales ¥67,160 million (YoY +17.1%) / Operating profit ¥8,025 million (YoY +12.4%) / United States Net Sales ¥10,344 million (YoY +2.3%) / Operating profit ¥-403 million (YoY -194.3%) / Europe Net Sales ¥13,351 million (YoY +15.7%) / Operating profit ¥717 million (YoY +218.5%) / Other Net Sales ¥2,078 million (YoY +22.0%) / Operating profit ¥153 million (YoY +29.3%)
Breakdown of Factors Affecting the ChangeChange in operating income Higher profits at EYS, China, Rohto standalone, Malaysia, DAX, etc. 8,187 / Higher profits at Rohto standalone and QTP 191 / Lower profits in Vietnam, China, DAX, etc. -1,208 / Lower profits in China, Malaysia, EYS, etc. -1,132 / Lower profits in China, Rohto standalone, etc. -264 / Impact of personnel expenses, etc. -1,903 / Other factors contributing to lower profits -2,233 / Operating income impact Foreign exchange impact 889 / Impact of higher sales 8,100 / Impact of personnel expenses -1,900 / Cost impact 190
Key KPIsIndicator name EBITDA / Value ¥30,071 million / Year on year against the same period last year ¥9.8 million, Indicator name Hada Labo sales / Value Not disclosed / Year on year against the same period last year 5.6 +5.6% year on year, Indicator name Rohto V5 sales / Value Not disclosed / Year on year against the same period last year 13.8 +13.8% year on year, Indicator name Obagi sales / Value Not disclosed / Year on year against the same period last year 3.5 +3.5% year on year, Indicator name Premium eye-drop sales / Value Not disclosed / Year on year against the same period last year 9.8 +9.8% year on year, Indicator name Melano CC sales / Value Not disclosed / Year on year against the same period last year -5.8 -5.8% year on year, Indicator name Sunscreen sales / Value Not disclosed / Year on year against the same period last year -18.1 -18.1% year on year
Assumptions Underlying the Business OutlookForeign exchange (USD/JPY) 158 / Foreign exchange (CNY/JPY) 23
Medium-term management plan targetsOperating cash flow (before deducting R&D expenses) ¥380 billion (six years from 2026 through 2031) / Capital Expenditure ¥110 billion (six years from 2026 through 2031) / Research and Development Expenses ¥100 billion (six years from 2026 through 2031) / DX/IT investment ¥35 billion (six years from 2026 through 2031) / M&A and other activities ¥70 billion (six years from 2026 through 2031)
Financial targetsPayout ratio At least 30% / DOE 3.5% or higher / 2030 dividend payout ratio Expected to be 40%
Annual DividendAnnual ¥50 / Interim ¥25 / End of period ¥25
Payout ratio31.9
Acquisition of treasury sharesAmount ¥3 billion / Period Ended on 14 September 2026
Capital expenditures¥10,485 million (interim period)
New initiativesStrategic Enterprise Partnership Agreement with the Hong Kong government’s OASES, Holding a Global Sustainability Meeting, Establishment of a voluntary review committee composed solely of independent outside directors, Acquisition of the Pain Away brand business and commencement of operations, Acquisition of Magic Cod d.o.o., Launch of phyto-exosome technology as a mass-market self-brand next spring
Items this document does not state (8)
Self-assessment against the planUnit price and quantity metricsNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookOrders received and order backlogMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Revenue increased in all regions. In particular, higher revenue in Asia and Europe, together with improved cost ratios resulting from price revisions for products such as Hada Labo in Japan, contributed to higher operating profit. Factors contributing to the decline in profit included lower shipments of eye drops in the United States, higher raw material and fuel costs, and foreign exchange losses.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.